Leucine-rich repeat serine/threonine-protein kinase 2

BE0009457ProteinHumansLRRK2

Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:21850687, PubMed:22012985, PubMed:23395371, PubMed:24687852, PubMed:25201882, PubMed:26014385, PubMed:26824392, PubMed:27830463, PubMed:28720718, PubMed:29125462,... It is acted on by 1 drug in DrugBank.

Gene name
LRRK2
UniProtKB entry
Q5S007Swiss-Prot
Cellular location
Cytoplasmic vesicle
Residues / weight
2,527 residues · 286,100 Da
Also known as
2.7.11.1 · 3.6.5.- · Dardarin · PARK8

Resolves to

Protein
UniProtQ5S007UniProt nameLRRK2_HUMAN
Gene
HGNCHGNC:18618NCBI Gene120892GeneCardsLRRK2
Pharmacology
IUPHAR/GtoPdb2059KEGGhsa:120892
Structure
PDB2ZEJPDB3D6TPDB5MY9
Drugs

What you can answer from here — as of September 07, 2019

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
32GO termsFunction, process and component, as structured annotations
Sign in
8Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
54+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Leucine-rich repeat serine/threonine-protein kinase 2, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In